Drs. Dan Veljovich and Selina Liu joined as faculty at the BTF’s Northwest Women’s Cancer Conference in Portland, Oregon on September 17, 2022.
Our staff, Tiani, sat down with Dr. Veljovich and Dr. Liu to discuss their roles in the conference and how they relate to the Binaytara Foundation’s mission of improving access to cancer care through education, advocacy, and innovation.
Dr. Veljovich, an oncologist at Swedish Cancer Institute, hopes to give back by sharing his expertise in ovarian cancer. Dr. Veljovich says he finds the foundation’s mission very compelling.
Dr. Liu is a Hematology/Oncology Fellow at Oregon Health and Science University. Dr. Liu says she was excited to present a case at the BTF’s Northwest Women’s Cancer Conference because it is also an opportunity to learn while sharing knowledge and contributing to the foundation’s goal of educating healthcare providers about the latest developments in the management of cancer.
Watch the video to hear more!
2022 Summit on Cancer Health Disparities ASCO award Binaytara foundation Binaytara Foundation Cancer Center Binaytara Foundation education academy breast cancer BTF cancer cancer care cancer disparities cancer research cancer treatment cancer treatment in Nepal CME community oncologists conference Conferences continuing education Dr. Binay Shah Dr. Rubina Suwal events Expert Opinion faculty faculty highlight FDA approved Featured head & neck cancer surgery in Nepal healthcare equity hematological malignancies Journal leukemia Lung cancer lymphoma multiple myeloma Nepal Nepal cancer care oncology oncology CME Opinion peer-reviewed journal SCHD upcoming conferences video news Volunteer
By Dr. Inas Abuali Massachusetts General Hospital There is a paucity of available treatment options for patients with advanced papillary renal
MoreOn March 4, 2023, the U.S. Food and Drug Administration approved expanded use of adjuvant abemaciclib with endocrine therapy for adult patients
MoreOn February 9th, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly for adult patients with recurrent or advanced endometrial cancer (EC)
MoreDr. Daneng Li of City of Hope Comprehensive Cancer Center shares a recent abstract from ASCO GI, NRG/RTOG 1112, a randomized phase
MoreOn January 27, 2023, the U.S. Food and Drug Administration approved elacestrant for postmenopausal, non-pregnant women and adult men with advanced or
More